Abstract
Although prostate cancer initially responds and regresses in response to androgen-depletion therapy, most human prostate cancers will re-grow as an androgen-independent tumour. The goal of our study was to apply functional genomics to identify gene expression changes involved in this process. Two high-throughout technologies, cDNA microarrays and tissue micorarrays, were applied to explore the molecular mechanisms underlying hormone-refractory prostate cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
